Camrelizumab, a PD-1 inhibitor developed in China, targets PD-1 on CD4+ and CD8+ T lymphocytes, B cells, and natural killer cells, effectively countering PD-1-mediated immunosuppression and preventing tumor immune escape. This evidence concerns the gene CD8A and neoplasm.